ASND · Categories · Downgrades
ASND - Analyst downgrades
Ascendis Pharma A/S (ASND) analyst downgrades - real-time wire coverage filtered to Downgrades only.
Recent Downgrades for ASND
- Ascendis Pharma downgraded by OppenheimerOppenheimer downgraded Ascendis Pharma from Outperform to Perform
- Ascendis Pharma downgraded by Morgan Stanley with a new price targetMorgan Stanley downgraded Ascendis Pharma from Overweight to Equal-Weight and set a new price target of $108.00 from $151.00 previously
- Ascendis Pharma downgraded by Credit SuisseCredit Suisse downgraded Ascendis Pharma from Outperform to Neutral
- Ascendis Pharma downgraded by B of A Securities with a new price targetB of A Securities downgraded Ascendis Pharma from Buy to Neutral and set a new price target of $169.00 from $164.00 previously
- Ascendis Pharma downgraded by OppenheimerOppenheimer downgraded Ascendis Pharma from Outperform to Perform